Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Yahoo Finance ·
The past few years have been challenging for Moderna ( MRNA -2.78% ) whose results haven't been as strong as demand for its COVID vaccine has diminished drastically. Lately, however, there's been a sharp and sudden surge in its share price. The stock has been acting like a volatile biotech stock that just obtained approval for a new drug. While that isn't the case, there's been a flurry of hype and excitement around a personalized cancer vaccine that it's been working on with Merck . It's a promising growth opportunity for both companies. But with Moderna already soaring more than 550% this year, has it gotten too expensive to buy right now?
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
345 participants
Related News
- MongoDB CEO Chirantan Desai Steps Down to Join Meta as Chief Enterprise Platform Officer
- Marvell Has Revenue Acceleration Potential in 2027, 2028, RBC Says
- Chip stocks fall as AI breach fuels safety concerns, but Nvidia bucks the trend: Chart of the Day
- Nvidia Announces Largest Buyback In History. Cramer Says “It Will Change Trajectory Of The Stock” If The Buyback Is Active
- Burford Capital shares gain on $5.7B Apple patent verdict
- Why Your Energy Bill Is About to Skyrocket $1,465 a Year Higher — Unless This Happens
